Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
22.36
+0.36 (1.64%)
Feb 5, 2025, 11:47 AM EST - Market open
Company Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Samuel Kintz |
Contact Details
Address: 6200 Lookout Road Boulder, Colorado 80301 United States | |
| Phone | 720 647 8519 |
| Website | enliventherapeutics.com |
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| Employer ID | 81-1523849 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Samuel Kintz | Chief Executive Officer |
| Benjamin Hohl | Chief Financial Officer |
| Anish Patel | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 27, 2025 | 144 | Filing |
| Jan 14, 2025 | 144 | Filing |
| Jan 14, 2025 | 144 | Filing |
| Jan 7, 2025 | 144 | Filing |
| Jan 3, 2025 | 144 | Filing |
| Dec 27, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |